Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 1
2014 1
2015 1
2016 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
In Vitro Gluten Challenge Test for Celiac Disease Diagnosis.
Khalesi M, Jafari SA, Kiani M, Picarelli A, Borghini R, Sadeghi R, Eghtedar A, Ayatollahi H, Kianifar HR. Khalesi M, et al. Among authors: eghtedar a. J Pediatr Gastroenterol Nutr. 2016 Feb;62(2):276-83. doi: 10.1097/MPG.0000000000000917. J Pediatr Gastroenterol Nutr. 2016. PMID: 26196202 Review.
Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Hamadani M, Khanal M, Ahn KW, Litovich C, Chow VA, Eghtedar A, Karmali R, Winter A, Fenske TS, Sauter C, Kharfan-Dabaja MA, Awan FT. Hamadani M, et al. Among authors: eghtedar a. Biol Blood Marrow Transplant. 2020 Jun;26(6):1099-1105. doi: 10.1016/j.bbmt.2020.02.025. Epub 2020 Mar 9. Biol Blood Marrow Transplant. 2020. PMID: 32165327 Free PMC article.
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes J. Eghtedar A, et al. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):477-84. doi: 10.1016/j.clml.2013.02.025. Epub 2013 Jun 14. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23770156 Free PMC article.
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Eghtedar A, et al. Blood. 2012 May 17;119(20):4614-8. doi: 10.1182/blood-2011-12-400051. Epub 2012 Mar 15. Blood. 2012. PMID: 22422826 Free PMC article. Clinical Trial.
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.
Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver N, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce S, Cortes J, Ravandi F. Eghtedar A, et al. Leuk Lymphoma. 2015 May;56(5):1342-5. doi: 10.3109/10428194.2014.953143. Epub 2014 Nov 3. Leuk Lymphoma. 2015. PMID: 25120050 Free PMC article.